In order to encourage policy formation and decision-making based on sound science at the federal level, ARHP often provides expert testimony in front of federal government decision making bodies and committees. ARHP has provided testimony on various reproductive health care topics including emergency contraception, the safety and efficacy of oral contraceptives, approvals of new medical devices, and issues related to the effects of environmental toxins on reproductive health in front of various agencies and committees within the US Department of Health and Human Services (HHS). Please click on the links below to view ARHP’s expert testimony.

Statement to the Bisphenol A (BPA) Subcommittee of the Science Board to the Food and Drug Administration
Submitted in response to FDA meeting to discuss the draft assessment of BPA for use in food containers; Request for Public Comment FDA-2008-N-0038
September 16, 2008

Presentation to the ICCR Preparatory Meeting on toxic substances in personal care products and cosmetics;
Request for health care providers to be present during ICCR meetings
June 19th, 2008

Testimony Regarding Adiana Transcervical Sterilization System
Food and Drug Administration Obstetrics and Gynecology Devices, Panel of the Medical Devices Advisory Committee
December 13, 2007

Statement in Support of Warnings Regarding Bisphenol A’s Possible Adverse Effects on Human Reproductive Health and Carcinogenicity
Presented to the National Toxicology Program’s Center for the Evaluation of Risks To Human Reproduction’s Second Bisphenol A Expert Panel Meeting
August 6, 2007

Measuring hormonal contraceptive efficacy
Testimony Presented to the United States Food and Drug Administration’s Advisory Committee for Reproductive Health Drugs
January 24, 2007

Statement in Support of the Approval of the HPV Vaccine
Presented to the United States Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee
May 18, 2006